Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
CAMBRIDGE, Mass., March 07, 2017 -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ for human metabolism, today announced that it will report financial results for the full year ended December 31, 2016, on Thursday, March 9, 2017. Following distribution of the earnings release via wire services, Dimension Therapeutics will host a live conference call and webcast at 8:30 a.m. Eastern Time to review the Company’s financial results and provide a business update.
Members of the Company’s management team will also be joined by Dr. Steven Pipe, Director of the Division of Pediatric Hematology and Oncology and Pediatric Medical Director of the Hemophilia and Coagulation Disorders Program at the C.S. Mott Children’s Hospital of the University of Michigan, and the lead investigator on the hemophilia B clinical trial.
The live webcast can be accessed by visiting the investor relations section of the Dimension Therapeutics website at www.dimensiontx.com. Please connect to the Company's website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Alternatively, please call 844-804-8784 (U.S.) or 210-229-8833 (International) to listen to the conference call. The conference ID number for the live call will be 84164743. An archive of the webcast will be available until March 23, 2017 on the investor relations section of the Company’s website.
About Dimension Therapeutics, Inc.
Dimension Therapeutics, Inc. (NASDAQ:DMTX) is a leader in discovering and developing new therapeutic products for people living with devastating rare and metabolic diseases associated with the liver, based on the most advanced mammalian adeno-associated virus (AAV) gene delivery technology. Dimension is actively progressing its broad pipeline, which features programs addressing unmet needs for patients suffering from inherited metabolic diseases, including OTC deficiency, GSDIa, citrullinemia type 1, PKU, Wilson disease, a collaboration with Bayer in hemophilia A, and a wholly owned clinical program in hemophilia B. Dimension has two phase 1/2 clinical trials for the treatment of hemophilia B and OTC deficiency. The company targets diseases with readily identifiable patient populations, highly predictive preclinical models, and well-described, and often clinically validated, biomarkers. Founded in 2013, Dimension maintains headquarters in Cambridge, Massachusetts.
For more information, please visit www.dimensiontx.com.
Contacts: Jean Franchi Chief Financial Officer Dimension Therapeutics 617-714-0709 [email protected] Burns McClellan, on behalf of Dimension Therapeutics Media: Justin Jackson 212-213-0006, ext.327 [email protected]
